Trial Profile
A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Hypoparathyroidism
- Focus Therapeutic Use
- Acronyms REPEAT
- Sponsors NPS Pharmaceuticals
- 10 Oct 2013 New trial record